MAM-6 antigen, a new serum marker for breast cancer monitoring.
MAM-6 antigen, a new serum marker for breast cancer monitoring.
复制标题
MAM-6 抗原，一种用于乳腺癌监测的新血清标记物。
作者：
John Hilkens;V. Kroezen;J. Bonfrer;M. Jong;Peter F. Bruning
几乎所有的癌症都含有一种细胞表面抗原MAM-6，它已经被几种单抗定义，包括115D8(Hilkens等人，Int.癌症杂志，34：197-206,1984)。以115D8为捕捉剂和示踪抗体，建立了检测血清中MAM-6的双抗体夹心放射免疫法。为了定量测定MAM-6水平，以混合母乳为标准，并选择任意单位。在表面健康的人血清中，只有不到5%的血清中含有5个单位/毫升以上的单位。在乳腺良性病变患者的血清中，也检测到了同样的低水平。然而，在病理I、II、III和IV期乳腺癌患者中，分别有24、21、43和79%的患者血清浓度超过5U/ml。几乎所有晚期卵巢癌患者的血清中MAM-6水平都升高，但来自其他晚期癌症患者的血清中MAM-6水平很低。为验证MAM-6作为监测乳腺癌治疗反应的临床标志物的可行性，进行了纵向研究。血清MAM-6水平的升高或降低在93%的乳腺癌进展或消退病例中具有相关性，表明该检测可用于监测治疗过程中的病程。在一些乳腺癌患者中，在肿瘤复发的任何临床迹象之前就观察到MAM-6水平升高。
Almost all carcinomas contain a cell surface antigen, MAM-6, which has been defined by several monoclonal antibodies, including 115D8 (Hilkens et al., Int. J. Cancer, 34: 197-206, 1984). A quantitative sandwich radioimmunoassay, using 115D8 as catcher and as tracer antibody, has been developed to detect MAM-6 in serum. To quantitate the MAM-6 level, pooled human milk was used as a standard, and arbitrary units were chosen. Less than 5% of the sera of apparently healthy individuals contained more than 5 units/ml. In sera of patients with benign breast lesions, the same low levels were detected. However, concentrations over 5 units/ml were found in 24, 21, 43, and 79% of the sera of patients with pathological Stages I, II, III, and IV breast cancer, respectively. MAM-6 levels were also increased in almost all sera tested from patients with advanced stages of ovarian carcinoma, but in a low percentage of sera from patients with other advanced cancers. A longitudinal study was carried out to test the MAM-6 assay as clinical marker to monitor the therapeutic response of breast cancer. Increasing or decreasing MAM-6 serum levels correlated in 93% of the cases with breast cancer progression or regression, indicating that the assay can be used to monitor the course of the disease during therapy. In some breast cancer patients, elevated MAM-6 levels were observed prior to any clinical indication of tumor recurrence.
登录
查看更多内容
针对人乳腺癌的单克隆抗体（F36/22 和 M7/105）。
影响因子：
11.2
作者：
Papsidero,LD;Croghan,GA;O'Connell,MJ;Valenzuela,LA;Nemoto,T;Chu,TM
通讯作者：
Chu,TM
影响因子：
56.9
作者：
KOPROWSKI, H;HERLYN, M;SEARS, HF
通讯作者：
SEARS, HF
双决定簇放射免疫分析中使用单克隆抗体检测胃肠道肿瘤患者血清中的癌胚抗原和相关抗原。
影响因子：
--
作者：
Herlyn,M;Blaszczyk,M;Sears,HF;Verrill,H;Lindgren,J;Colcher,D;Steplewski,Z;Schlom,J;Koprowski,H
通讯作者：
Koprowski,H
DOI：
10.1073/pnas.79.17.5420
发表时间：
1982-01-01
期刊：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES
影响因子：
--
作者：
CERIANI, RL;SASAKI, M;BLANK, EW
通讯作者：
BLANK, EW